Takeda’s Vedolizumab Clears Phase III in aGvHD

Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease (aGvHD), the company announced Saturday.